Terns Pharmaceuticals, Inc. (TERN)
NASDAQ$3.18
Market Cap
$270.11M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
67 of 924
Rank in Industry
47 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
TERN Insider Trading Activity
TERN Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $5,167,110 | 6 | 25 |
Sells | $4,674,820 | 18 | 75 |
Related Transactions
| Lu Hongbo | director | 1 | $5M | 0 | $0 | $5M |
| Burroughs Amy L. | Chief Executive Officer | 2 | $113,074 | 0 | $0 | $113,074 |
| Yoon Seokho Bryan | COO and General Counsel | 1 | $21,272 | 0 | $0 | $21,272 |
| Vignola Mark J. | Chief Financial Officer | 1 | $21,272 | 3 | $209,024 | $-187,751 |
| Jung Melita Sun | Chief Business Officer | 1 | $11,498 | 0 | $0 | $11,498 |
| Kuriakose Emil | Chief Medical Officer | 0 | $0 | 1 | $25,607 | $-25,607 |
| Quigley Jill M. | director | 0 | $0 | 7 | $520,050 | $-520,050 |
| GORDON CARL L | 0 | $0 | 2 | $561,640 | $-561,640 | |
| ORBIMED ADVISORS LLC | 0 | $0 | 2 | $561,640 | $-561,640 | |
| Vivo Opportunity, LLC | 10 percent owner | 0 | $0 | 3 | $2.8M | $-2.8M |
About Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor …
Insider Activity of Terns Pharmaceuticals, Inc.
Over the last 12 months, insiders at Terns Pharmaceuticals, Inc. have bought $5.17M and sold $4.67M worth of Terns Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Terns Pharmaceuticals, Inc. have bought $15.43M and sold $6.46M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Lu Hongbo (director) — $5M. Burroughs Amy L. (Chief Executive Officer) — $113,074. Yoon Seokho Bryan (COO and General Counsel) — $21,272.
The last purchase of 15,450 shares for transaction amount of $110,468 was made by Burroughs Amy L. (Chief Executive Officer) on 2024‑12‑05.
List of Insider Buy and Sell Transactions, Terns Pharmaceuticals, Inc.
| 2025-01-06 | Sale | Vignola Mark J. | Chief Financial Officer | 9,059 0.0108% | $5.80 | $52,500 | -24.96% | |
| 2025-01-06 | Sale | Quigley Jill M. | director | 8,760 0.0105% | $5.79 | $50,758 | -24.96% | |
| 2025-01-02 | Sale | Vignola Mark J. | Chief Financial Officer | 8,129 0.0098% | $5.72 | $46,524 | -23.55% | |
| 2025-01-02 | Sale | Kuriakose Emil | Chief Medical Officer | 4,481 0.0054% | $5.71 | $25,607 | -23.55% | |
| 2025-01-02 | Sale | Quigley Jill M. | director | 6,240 0.0075% | $5.72 | $35,702 | -23.55% | |
| 2024-12-05 | Burroughs Amy L. | Chief Executive Officer | 15,450 0.0201% | $7.15 | $110,468 | -29.97% | ||
| 2024-11-30 | Burroughs Amy L. | Chief Executive Officer | 510 0.0005% | $5.11 | $2,606 | -7.48% | ||
| 2024-11-30 | Jung Melita Sun | Chief Business Officer | 2,250 0.0022% | $5.11 | $11,498 | -7.48% | ||
| 2024-09-12 | Lu Hongbo | director | 476,190 0.7471% | $10.50 | $5M | -37.85% | ||
| 2024-09-10 | Sale | Vignola Mark J. | Chief Financial Officer | 10,000 0.0139% | $11.00 | $110,000 | -47.20% | |
| 2024-09-09 | Sale | Quigley Jill M. | director | 17,235 0.0269% | $10.00 | $172,350 | -34.32% | |
| 2024-08-02 | Sale | Quigley Jill M. | director | 8,857 0.0138% | $7.50 | $66,432 | -11.80% | |
| 2024-08-01 | Sale | Quigley Jill M. | director | 6,143 0.0094% | $7.68 | $47,148 | -15.32% | |
| 2024-07-16 | Sale | ORBIMED ADVISORS LLC | 5,188 0.012% | $10.00 | $51,880 | -30.72% | ||
| 2024-07-16 | Sale | GORDON CARL L | 5,188 0.012% | $10.00 | $51,880 | -30.72% | ||
| 2024-07-16 | Sale | Quigley Jill M. | director | 400 0.0009% | $10.00 | $4,000 | -30.72% | |
| 2024-07-15 | Sale | ORBIMED ADVISORS LLC | 50,976 0.1182% | $10.00 | $509,760 | -32.73% | ||
| 2024-07-15 | Sale | GORDON CARL L | 50,976 0.1182% | $10.00 | $509,760 | -32.73% | ||
| 2024-07-15 | Sale | Quigley Jill M. | director | 14,365 0.0333% | $10.00 | $143,660 | -32.73% | |
| 2024-05-31 | Yoon Seokho Bryan | COO and General Counsel | 4,791 0.0055% | $4.44 | $21,272 | +14.23% |
Total: 47
*Gray background shows transactions not older than one year
Insider Historical Profitability
50.17%
| ORBIMED ADVISORS LLC | 755635 0.8896% | $2.4M | 2 | 2 | <0.0001% | |
| GORDON CARL L | 755635 0.8896% | $2.4M | 2 | 2 | <0.0001% | |
| Lu Hongbo | director | 476190 0.5606% | $1.51M | 3 | 0 | +60.18% |
| Vivo Opportunity, LLC | 10 percent owner | 268573 0.3162% | $854,062.14 | 1 | 3 | +0.36% |
| Yoon Seokho Bryan | COO and General Counsel | 91940 0.1082% | $292,369.20 | 5 | 0 | +77.68% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$99,438,720 | 81 | 6.74% | $290.44M | |
$69,130,029 | 69 | 25.63% | $240.78M | |
$11,468,215 | 44 | 17.78% | $246.73M | |
$17,983,739 | 41 | 102.87% | $266.1M | |
$18,554,304 | 31 | -11.72% | $241.52M |
TERN Institutional Investors: Active Positions
| Increased Positions | 105 | +68.18% | 21M | +27.13% |
| Decreased Positions | 67 | -43.51% | 13M | -16.81% |
| New Positions | 39 | New | 8M | New |
| Sold Out Positions | 34 | Sold Out | 5M | Sold Out |
| Total Postitions | 192 | +24.68% | 87M | +10.32% |
TERN Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Soleus Capital Management, L.P. | $30,046.00 | 9.58% | 8.14M | +2M | +30.83% | 2024-12-31 |
| Orbimed Advisors Llc | $27,907.00 | 8.9% | 7.56M | 0 | 0% | 2024-12-31 |
| Vivo Capital, Llc | $25,445.00 | 8.11% | 6.9M | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $21,193.00 | 6.76% | 5.74M | +1M | +22.23% | 2024-12-31 |
| Deep Track Capital, Lp | $20,577.00 | 6.56% | 5.58M | 0 | 0% | 2024-12-31 |
| Schonfeld Strategic Advisors Llc | $17,533.00 | 5.59% | 4.75M | +1M | +44.43% | 2024-12-31 |
| Vanguard Group Inc | $14,279.00 | 4.55% | 3.87M | +512,768 | +15.28% | 2024-12-31 |
| Morgan Stanley | $12,353.00 | 3.94% | 3.35M | +3M | +327.6% | 2024-12-31 |
| Citadel Advisors Llc | $12,058.00 | 3.84% | 3.27M | -405,447 | -11.04% | 2024-12-31 |
| Nuveen Asset Management, Llc | $9,719.00 | 3.1% | 2.63M | +617,009 | +30.59% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.